Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nippon Zoki, Teikoku Seiyaku to Codevelop Adhesive Agent for PHN
June 6, 2011
- Daiichi Sankyo Aims for Sales of ¥40 Bil. in China
June 6, 2011
- HPV Vaccine Gardasil Recommended for Approval
June 6, 2011
- ¥45.5 Billion Worth of New-type Flu Vaccines Discarded: Health Minister Hosokawa
June 6, 2011
- Astellas Looking for Partner for Global Development of Darexaban
June 6, 2011
- ASKA's Emergency Pill Priced at ¥10,000/Dose
June 6, 2011
- Teijin Pharma to Collect More Evidence on Efficacy of Feburic for Hyperuricemia
June 6, 2011
- JPA Opposes Drug Price Revision without Revision of Medical, Nursing Fees
June 6, 2011
- Santen Regains Top Spot in Domestic Glaucoma Market
June 6, 2011
- Sitagliptin Approved for Combination Therapy with αGI: MSD, Ono
June 6, 2011
- Seikagaku Preparing to Launch Gel-One in US Despite Patent Dispute
June 6, 2011
- Pfizer Files Simultaneous Application for Crizotinib in the US, Japan
June 6, 2011
- Kyorin HD: Double-Digit Growth in Sales, Profits Driven by Kipres
June 6, 2011
- Chugai Applies for Pediatric Use, Dosage of CellCept
June 6, 2011
- Kaken: Operating Profits Up 20%
June 6, 2011
- BM Files for Breast Cancer for Paraplatin Based on Public Knowledge
June 6, 2011
- Mochida: Net Profits Down 46% due to Earthquake
June 6, 2011
- Korosho Designates Velaglucerase Alfa as Orphan Drug for Gaucher's Disease
June 6, 2011
- Kissei: Sales Up 3.6% Driven by Major Products Including Urief
June 6, 2011
- 17 Companies to List Actos Generics in June, 9 to Delay Listing
June 6, 2011
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…